There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

Gasherbrum Bio Inc. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, schizophrenia, hypertension, obesity, ...

MONDAY, March 3, 2025 (HealthDay News) — Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar ...

Opens in a new tab or window Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...